Clinical Outcomes of Pembrolizumab Combination Therapy in Heavily Pretreated PDTC and Anaplastic Thyroid Cancer.
BACKGROUND Poorly differentiated (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive malignancies with limited treatment options. Although targeted therapies for tumours harbouring BRAF V600E mutations or fusions involving NTRK1, NTRK2, NTRK3, or RET have expanded treatment options, most patients lack su...